In recent years, various novel models and nomograms were developed to improve the diagnostic performance of PCa, which utilizes one or more of following tools or biomarkers: serum prostate-specific antigen density (PSA), PSAD, age, history of prior prostate biopsy, DRE, radiomics, genomics, and molecular imaging (9, 10). The gene discussed is KLK3; the disease is posterior cortical atrophy.